Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease
DOI:
https://doi.org/10.33393/grhta.2024.3062Keywords:
Anaemia, Chronic kidney disease, Economic evaluation, RoxadustatAbstract
Objective: The aim of this study was to evaluate the economic consequences of the introduction of roxadustat on the market as treatment for chronic kidney disease (CKD)-related anaemia in Italy.
Method: A budget impact model was developed to assess the economic impact of the introduction of roxadustat for the management of patient with CKD-related anaemia. The analysis was conducted considering National Health Service (NHS) perspective and three years’ time horizon. Eligible population for the treatment with roxadustat was estimated through published literature and clinicians’ support. Direct healthcare costs included drug acquisition (list prices for base case) and administration costs, monitoring costs, cost per blood transfusion, costs related to the management of adverse events and dialysis costs.
Results: The model estimated a three years expenditure associated with the management of patients with CKD-related incident anaemia in Italy of about € 260 and € 44.6 million for non-dialysis dependent (NDD) and dialysis-dependent (DD) patients respectively. The introduction of roxadustat on the market could generate a reduction in the expenditure related to the iron supplementation both for NDD and for DD patients (−€ 397,305 and −€ 50,135 over three years of the analysis, respectively) and a reduction in the pharmaceutical expenditure for NDD patients (−€ 2.3 million, −€ 7.5 million and −€ 13 million at first, second and third year of the analysis). Overall, the introduction of roxadustat could generate a saving for NHS approximately equal to € 2.3, € 7.5 and € 13 million at first, second and third year of the analysis.
Conclusion: The introduction of roxadustat could generate a reduction in the expenditure for the management of patients with CKD anaemia. A scenario analysis which used tender prices for ESAs and hypothesis of confidential discount for roxadustat showed that the saving for NHS will be kept if roxadustat’s discount is greater than 60.3%.
Downloads
References
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1). Online https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. (Accessed March 2024)
Mennini FS. M.A., Viti R, Bini C, Maffei P, Pivonello R, Analisi di impatto di budget di pasireotide in pazienti con acromegalia nella prospettiva del Sistema Sanitario Nazionale. IN PUBBLICATION; 2016.
Cases-Amenós A, Martínez-Castelao A, Fort-Ros J, et al; Investigadores del Estudio Micenas I. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. Nefrologia. 2014;34(2):189-198. PMID:24658193
De Nicola L, Minutolo R, Chiodini P, et al; SIN-TABLE CDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. Am J Nephrol. 2010;32(6):533-540. https://doi.org/10.1159/000321468 PMID:20980739 DOI: https://doi.org/10.1159/000321468
Minutolo R, Locatelli F, Gallieni M, et al; REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant. 2013;28(12):3035-3045. https://doi.org/10.1093/ndt/gft338 PMID:24145459 DOI: https://doi.org/10.1093/ndt/gft338
Wong MMY, Tu C, Li Y, et al; CKDopps Investigators. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2019;13(4):613-624. https://doi.org/10.1093/ckj/sfz091 PMID:32905241 DOI: https://doi.org/10.1093/ckj/sfz091
Portolés J, Gorriz JL, Rubio E, et al; NADIR-3 Study Group. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14(2):2. https://doi.org/10.1186/1471-2369-14-2 PMID:23295149 DOI: https://doi.org/10.1186/1471-2369-14-2
DOPPS Practice Monitor-Hemodialysis DPM. Online https://www.dopps.org/DPM-HD/DPMSlideBrowser.aspx?type=Topic&id=1&g=hgbgdl_c_overall. (Accessed March 2024)
Toft G, Heide-Jørgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33(1):147-156. https://doi.org/10.1007/s40620-019-00652-9 PMID:31587136 DOI: https://doi.org/10.1007/s40620-019-00652-9
Minutolo R, Provenzano M, Chiodini P, et al; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology. New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study. Clin Kidney J. 2022;15(6):1120-1128. https://doi.org/10.1093/ckj/sfac004 PMID:35664282 DOI: https://doi.org/10.1093/ckj/sfac004
De Nicola L, Chiodini P, Zoccali C, et al; SIN-TABLE CKD Study Group. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol. 2011;6(10):2421-2428. https://doi.org/10.2215/CJN.01180211 PMID:21817127 DOI: https://doi.org/10.2215/CJN.01180211
Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. Am J Kidney Dis. 2009;54(6):1052-1061. https://doi.org/10.1053/j.ajkd.2009.07.021 PMID:19800722 DOI: https://doi.org/10.1053/j.ajkd.2009.07.021
Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. Kidney Int Suppl (2011). 2017 Dec;7(3):157-163. doi: 10.1016/j.kisu.2017.09.002 PMID: 30675430 DOI: https://doi.org/10.1016/j.kisu.2017.09.002
Kidney Disease: Improving Global Outcomes (KDIGO), KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:279-335. Online https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf (Accessed March 2024)
Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791-798. https://doi.org/10.1038/ki.2008.295 PMID:18596733 DOI: https://doi.org/10.1038/ki.2008.295
Bae MN, Kim SH, Kim YO, et al. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients. PLoS One. 2015;10(11):e0143348. https://doi.org/10.1371/journal.pone.0143348 PMID:26588085 DOI: https://doi.org/10.1371/journal.pone.0143348
Fujii H, Hamano T, Tsuchiya K, et al; PARAMOUNT Study Investigators. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study. Int J Cardiol. 2023;375:110 118. https://doi.org/10.1016/j.ijcard.2022.12.051 PMID:36592827 DOI: https://doi.org/10.1016/j.ijcard.2022.12.051
Locatelli F, et al. Il trattamento dell’anemia del paziente con malattia renale cronica: dopo un viaggio lungo oltre 30 anni quali evidenze supportano la scelta motivata di un ESA? G Ital Nefrol. 2020;4(5).
Locatelli F, Del Vecchio L. Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs? J Am Soc Nephrol. 2022;33(11):1966-1979. https://doi.org/10.1681/ASN.2022040413 PMID:36041790 DOI: https://doi.org/10.1681/ASN.2022040413
Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36(9):1717-1730. https://doi.org/10.1093/ndt/gfab051 PMID:33629100 DOI: https://doi.org/10.1093/ndt/gfab051
Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336-347. https://doi.org/10.1111/j.1524-4733.2007.00187.x PMID:17888098 DOI: https://doi.org/10.1111/j.1524-4733.2007.00187.x
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5-14. https://doi.org/10.1016/j.jval.2013.08.2291 PMID:24438712 DOI: https://doi.org/10.1016/j.jval.2013.08.2291
European Medicines Agency (EMA). RCP Roxadustat. Online https://www.ema.europa.eu/en/documents/product-information/evrenzo-epar-product-information_it.pdf. (Accessed March 2024)
ISTAT. Popolazione residente per sesso, età e stato civile al 1° Gennaio 2022. Online https://demo.istat.it/app/?i=POS#:~:text=Popolazione%20residente%3A%20%C3%A8%20costituita%20dalle,Comune%20italiano%20o%20all'estero. (Accessed March 2024)
De Nicola L, Donfrancesco C, Minutolo R, et al; ANMCO-SIN Research Group. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008-12 National Health Examination Survey. Nephrol Dial Transplant. 2015;30(5):806-814. https://doi.org/10.1093/ndt/gfu383 PMID:25523453 DOI: https://doi.org/10.1093/ndt/gfu383
Viscogliosi G, De Nicola L, Vanuzzo D, Giampaoli S, Palmieri L, Donfrancesco C; HES Research Group. Mild to moderate chronic kidney disease and functional disability in community-dwelling older adults. The Cardiovascular risk profile in Renal patients of the Italian Health Examination Survey (CARHES) study. Arch Gerontol Geriatr. 2019;80:46-52. https://doi.org/10.1016/j.archger.2018.10.001 PMID:30343147 DOI: https://doi.org/10.1016/j.archger.2018.10.001
The CAPRI study: CKD Anemia Prevalence, Incidence, treatment patterns and healthcare resource utilization in non dialysis patients in Italy. A retrospective study of electronic medical records.”. 2021.(Astellas Data on File)
Real World Analysis on administrative database – Anemia in dialysis dependent CKD patients. 2021.(Astellas Data on File)
Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36(9):1616-1628. https://doi.org/10.1093/ndt/gfab191 PMID:34077510 DOI: https://doi.org/10.1093/ndt/gfab191
Decreto del Ministero della Salute 18 ottobre 2012. Tariffe delle prestazioni di assistenza specialistica ambulatoriale. Online http://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=3&art=1&subart=1&subart1=10&vers=1&prog=001. (Accessed March 2024)
Fliser D, Mata Lorenzo M, Houghton K, et al. Real-Life Anemia Management Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Three European Countries. Int J Nephrol Renovasc Dis. 2023;16:115-129. https://doi.org/10.2147/IJNRD.S401598 PMID:37077414 DOI: https://doi.org/10.2147/IJNRD.S401598
Cases A, Sánchez EGA, Cadeddu G, Lorenzo MM. Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study. Nefrologia (Engl Ed). 2023;43(5):562-574. https://doi.org/10.1016/j.nefroe.2023.10.004 PMID:37914638 DOI: https://doi.org/10.1016/j.nefroe.2023.10.004
Theidel U, Asseburg C, Giannitsis E, Katus H. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol. 2013;102(6):447-458. https://doi.org/10.1007/s00392-013-0552-7 PMID:23474908 DOI: https://doi.org/10.1007/s00392-013-0552-7
Lok CE, Bhola C, Croxford R, Richardson RM. Reducing vascular access morbidity: a comparative trial of two vascular access monitoring strategies. Nephrol Dial Transplant. 2003;18(6):1174-1180. https://doi.org/10.1093/ndt/gfg122 PMID:12748352 DOI: https://doi.org/10.1093/ndt/gfg122
Decreto del Ministero della Salute 18 ottobre 2012. Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero. Online http://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001. (Accessed March 2024)
Ministero della Salute. Rapporto annuale sull’attività di ricovero ospedaliero. Dati SDO 2019. Online https://www.salute.gov.it/imgs/C_17_pubblicazioni_3002_allegato.pdf. (Accessed March 2024)
Sciattella P, et al. Rehospitalization due to subsequent cardiovascular events in secondary prevention patients treated with lipid lowering therapies in Italy. Poster PCV84. 2019; Online https://www.valueinhealthjournal.com/article/S1098-3015(19)33186-9/pdf. (Accessed March 2024) DOI: https://doi.org/10.1016/j.jval.2019.09.808
Registro Italiano di Dialisi e Trapianto. Report 2017. Online https://ridt.sinitaly.org/2019/10/08/report-2017/. (Accessed March 2024)
Dipartimento di Epidemiologia Lazio. Registro Dialisi e Trapianto Lazio. Rapporto 2019. Online https://www.dep.lazio.it/prevale2020/documenti/dialisi/rapporto_rrdtl2019.pdf. (Accessed March 2024)
Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019;22(6):593-604. https://doi.org/10.1080/13696998.2019.1588738 PMID:30813807 DOI: https://doi.org/10.1080/13696998.2019.1588738
Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer’s perspective. Dis Manag. 2008;11(1):49-58. https://doi.org/10.1089/dis.2008.111715 PMID:18279115 DOI: https://doi.org/10.1089/dis.2008.111715
Liu J, Guo H, Gilbertson D, Foley R, Collins A. Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis. Ther Clin Risk Manag. 2009;5(4):319-330. https://doi.org/10.2147/TCRM.S4856 PMID:19753126 DOI: https://doi.org/10.2147/TCRM.S4856
Gazzetta Ufficiale n.48 del 25/02/2023. Online https://www.gazzettaufficiale.it/eli/gu/2023/02/25/48/sg/pdf. (Accessed March 2024)
Farmadati. Last Access Date: 30/09/2023. Online https://www.farmadati.it/.
Roxadustat Vs ESAs in Dialysis-Dependent Chronic Kidney Disease: pooled analysis of four Phase 3 studies. 2021. .(Astellas Data on File)
Csiky B, Schömig M, Esposito C, et al. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Adv Ther. 2021;38(10):5361-5380. https://doi.org/10.1007/s12325-021-01904-6 PMID:34537926 DOI: https://doi.org/10.1007/s12325-021-01904-6
Agenzia Italiana del Farmaco (AIFA). Riassunto delle caratteristiche del prodotto NeoRecormon. Online https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004768_034430_RCP.pdf&sys=m0b1l3#:~:text=NeoRecormon%20%C3%A8%20indicato%20per%3A,gestazione%20inferiore%20a%2034%20settimane. (Accessed March 2024)
Agenzia Italiana del Farmaco (AIFA). Riassunto delle caratteristiche del prodotto Mircera. Online https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004768_038348_RCP.pdf&sys=m0b1l3. (Accessed March 2024)
Analisi prezzi medi gare ospedaliere su dato IHS (Information Hospital Service).(Astellas Data on File)
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-07-01
Published 2024-09-10
